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Abstract
Introduction: The aim of this study was to investigate the effect of three years of tumor necrosis factor-alpha
(TNF-a) blocking therapy on bone turnover as well as to analyze the predictive value of early changes in bone
turnover markers (BTM) for treatment discontinuation in patients with ankylosing spondylitis (AS).
Methods: This is a prospective cohort study of 111 consecutive AS outpatients who started TNF-a blocking therapy.
Clinical assessments and BTM were assessed at baseline, three and six months, as well as at one, two, and three years.
Z-scores of BTM were calculated to correct for age and gender. Bone mineral density (BMD) was assessed yearly.
Results: After three years, 72 patients (65%) were still using their first TNF-a blocking agent. In these patients, TNF-a
blocking therapy resulted in significantly increased bone-specific alkaline phosphatase, a marker of bone formation;
decreased serum collagen-telopeptide (sCTX), a marker of bone resorption; and increased lumbar spine and hip BMD
compared to baseline. Baseline to three months decrease in sCTX Z-score (HR: 0.394, 95% CI: 0.263 to 0.591), AS disease
activity score (ASDAS; HR: 0.488, 95% CI: 0.317 to 0.752), and physician’s global disease activity (HR: 0.739, 95% CI: 0.600
to 0.909) were independent inversely related predictors of time to treatment discontinuation because of inefficacy or
intolerance. Early decrease in sCTX Z-score correlated significantly with good long-term response regarding disease
activity, physical function and quality of life.
Conclusions: Three years of TNF-a blocking therapy results in a bone turnover balance that favors bone formation,
especially mineralization, in combination with continuous improvement of lumbar spine BMD. Early change in sCTX
can serve as an objective measure in the evaluation of TNF-a blocking therapy in AS, in addition to the currently
used more subjective measures.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that mainly affects the axial skeleton. Bone for-
mation and bone loss are both present in AS. New bone
formation can lead to the formation of syndesmophytes,
ankylosis of the spine and sacroiliac joints, and bone
formations on enthesal sites [1,2], whereas bone loss can
result in osteoporosis and vertebral fractures [3-5].
Randomized controlled trials (RCTs) have shown that
the tumor necrosis factor-alpha (TNF-a) blocking
agents infliximab, etanercept and adalimumab are effec-
tive in controlling inflammation and improving clinical
assessments in AS [6-8]. Previous studies could not
demonstrate a significant effect of two years of TNF-a
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blocking therapy on radiographic progression in AS
[9-11].
Although the majority of patients responds very well, a
significant proportion of patients has to withdraw from
TNF-a blocking therapy due to inefficacy or adverse
events [12-14]. Currently, subjective measures of disease
activity, such as the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) or the global opinion of the phy-
sician, are most important in the evaluation of TNF-a
blocking therapy in AS. The recently developed Ankylos-
ing Spondylitis Disease Activity Score (ASDAS) captures
both subjective (patient-reported measures) and objective
(acute phase reactant) aspects of disease activity [14-17].
However, it would be useful to also include a purely objec-
tive measure in this evaluation process.
The early effect of TNF-a blocking therapy on bone
turnover may be helpful in predicting treatment outcome.
Bone turnover can be monitored using bone turnover
markers (BTM) [18]. The bone formation markers, bone-
specific alkaline phosphatase (BALP) and osteocalcin
(OC), were reported to be increased after 2 to 52 weeks
and 2 to 22 weeks of TNF-a blocking therapy, respectively
[19-21]. On the other hand, the bone resorption markers,
serum type I collagen N-telopeptide and C-telopeptide
(sNTX and sCTX), remained unchanged up to 46 weeks
of TNF-a blocking treatment [19,21,22]. Visvanthan et al.
showed that an early increase in BALP was associated with
significant increases in bone mineral density (BMD) of the
spine and hip after two years of TNF-a blocking therapy
[23].
The first aim of the present study was to investigate the
effect of three years of TNF-a blocking therapy on bone
turnover. The second aim was to investigate whether the
early effect of TNF-a blocking therapy on BTM can serve




Between November 2004 and December 2007, 111 conse-
cutive Dutch outpatients with AS, who started TNF-a
blocking therapy at the University Medical Center Gronin-
gen (UMCG; n = 28) and the Medical Center Leeuwarden
(MCL; n = 83), were included in this longitudinal analysis.
All patients participated in the Groningen Leeuwarden
Ankylosing Spondylitis (GLAS) study, a prospective longi-
tudinal observational cohort study with follow-up visits
according to a fixed protocol. For the present analysis,
patients with recent fractures and/or use of bisphospho-
nates were excluded because of major influence on bone
metabolism. All patients were over 18 years of age, fulfilled
the modified New York criteria for AS (n = 109) [24] or
the Assessments in Ankylosing Spondylitis (ASAS) criteria
for axial spondyloarthritis including MRI (n = 2) [25]. The
patients started treatment with the TNF-a blocking agents
infliximab (n = 22), etanercept (n = 71), or adalimumab
(n = 18) because of active disease (BASDAI ≥ 4 and/or
expert opinion), according to the ASAS consensus state-
ment [26]. As described previously [14], infliximab (5 mg/
kg) was given intravenously at zero, two and six weeks and
then every eight weeks. In case of inadequate response,
the frequency of infliximab treatment was raised to every
six weeks. Etanercept was administered as a subcutaneous
injection once (50 mg) or twice (25 mg) a week. Adalimu-
mab (40 mg) was administered as a subcutaneous injection
on alternate weeks. In 2004 and 2005, patients started
treatment with either infliximab or etanercept as adalimu-
mab was only registered in The Netherlands as of 2006.
The choice of the TNF-a blocking agent was based on the
judgment of the treating rheumatologist and/or the speci-
fic preference of the patient. Continuation of treatment
was based on a decrease in the BASDAI of at least 50% or
two units compared with baseline and/or expert opinion
in favor of treatment continuation. Reasons for disconti-
nuation of TNF-a blocking therapy were classified into
the categories: intolerance due to adverse events, inefficacy
or other reasons. Patients were allowed to receive conco-
mitant medication as usual in daily clinical practice. The
GLAS study was approved by the local ethics committees
of the UMCG and the MCL. All patients provided written
informed consent according to the Declaration of Helsinki.
Clinical and laboratory assessments
Patients were evaluated at baseline and after three months
(mean 3.3 mo, SD ± 0.5), six months (mean 6.4 mo, SD ±
0.8), one year (mean 1.0 yr, SD ± 0.1), two years (mean
2.1 yr, SD ± 0.1), and three years (mean 3.1 yr, SD ± 0.1)
of TNF-a blocking therapy. Disease activity was assessed
using the BASDAI (on a scale of 0 to 10), physician’s and
patient’s global assessment of disease activity (GDA; on a
scale of 0 to 10), erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), and ASDASCRP (calculated from
BASDAI questions 2, 3 and 6, patient’s GDA, and CRP)
[15,16]. Increased ESR and CRP levels were based on local
standardized values. Physical function was assessed using
the Bath Ankylosing Spondylitis Functional Index (BASFI;
on a scale of 0 to 10). Spinal mobility assessments included
chest expansion, modified Schober test, occiput to wall
distance and lateral lumbar flexion (left and right). Quality
of life was assessed using the Ankylosing Spondylitis Qual-
ity of Life questionnaire (ASQoL; on a scale of 0 to 18).
Peripheral arthritis was defined as at least one swollen
joint (excluding the hip) at baseline.
Bone turnover was studied by assessment of the bone
formation markers bone-specific alkaline phosphatase
(BALP) and procollagen type 1 N-terminal peptide (PINP),
and the bone resorption marker serum type I collagen C-
telopeptide (sCTX) [5]. BALP was measured by enzyme-
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linked immunosorbent assay (ELISA; Metra Biosystems,
Mountain View, CA, USA; inter-assay coefficient of varia-
tion (IE-CV) 5.5%), PINP by radioimmunoassay (RIA;
Orion Diagnostica, Espoo, Finland; IE-CV 9.0%), and sCTX
by electrochemiluminescence immunoassay (ECLIA;
Elecsys 2010 Roche Mannheim, Germany; IE-CV 10.8%).
Serum samples were stored within one hour at -20°C until
analysis.
Z-scores of BTM were used to correct for the normal
influence that age and gender have on bone turnover. Z-
scores, the number of standard deviations (SD) from the
normal mean corrected for age and gender, were calcu-
lated using matched 10-year-cohorts of a Dutch reference
group (200 men or 350 women) checked for serum 25-
hydroxyvitamin D levels > 50 nmol/liter as well as for the
absence of osteoporosis (BMD T-score > -2.5) after
50 years of age. Z-scores were calculated as follows: (BTM
value of individual patient - mean BTM value of matched
10-year-cohort of reference group)/SD of matched refer-
ence cohort.
BMD measurement
BMD of the lumbar spine (anterior-posterior projection at
L1 to L4) and hip (total proximal femur) was assessed at
baseline and after one year (mean 1.1 yr, SD ± 0.1), two
years (mean 2.2 yr, SD ± 0.2), and three years (mean
3.2 yr, SD ± 0.2) of TNF-a blocking therapy. BMD was
measured using DXA (Hologic QDR Discovery (UMCG)
or Hologic QDR Delphi (MCL), Waltham, MA, USA).
T-scores, the number of SD from the normal mean
obtained from young healthy adults, and Z-scores, the
number of SD from the normal mean corrected for age
and gender, were calculated using the NHANES reference
database. According to the World Health Organization
(WHO) classification, osteopenia was defined as a T-score
between -1 and -2.5 and osteoporosis as a T-score ≤ -2.5
[27].
Statistical analysis
Statistical analysis was performed with PASW Statistics 18
(SPSS, Chicago, IL, USA). Results were expressed as mean
± SD or median (range) for normally distributed and non-
normally distributed data, respectively. Predictor analysis
of time to discontinuation of TNF-a blocking therapy
(yes/no) was performed using forward conditional Cox
regression of variables with a P-value ≤ 0.3 in univariate
Cox regression. The probability of F for entry was 0.05.
Receiver Operating Characteristic (ROC) analysis was per-
formed to determine the accuracy of early change in BTM
to predict discontinuation of TNF-a blocking therapy dur-
ing the first three years. Area under the curve (AUC) <
0.70 was interpreted as poor accuracy, 0.70 < AUC < 0.90
as moderate accuracy, and AUC > 0.90 as high accuracy
[28]. Pearson’s and Spearman’s correlation coefficients
were used as appropriate to analyze the relation between
early change in BTM and clinical assessments. Generalized
estimating equations (GEE) were used to analyze clinical
assessments, BTM, and BMD over time within subjects.
Pairwise contrasts were used to compare baseline and fol-
low-up visits. P-values < 0.05 were considered statistically
significant.
Results
The mean age of the 111 AS patients was 42.2 years
(SD ± 10.3), 70% were male, and median disease dura-
tion was 16 years (range 1 to 49). All baseline character-
istics are shown in Table 1.
After three years, 72 patients (65%) continued to use
their first TNF-a blocking agent. In these patients, all
assessments of disease activity (Table 2), physical function,
spinal mobility and quality of life (data not shown)
improved after three months and remained significantly
better compared to baseline up to three years of TNF-a
blocking therapy.
The remaining 39 patients (35%) discontinued treatment
after a median follow-up of 7.0 months (range 1.1 to 36.2).
Reasons for discontinuation of TNF-a blocking therapy
were inefficacy (n = 17; 44%), adverse events (n = 11; 28%:
diarrhea or inflammatory bowel disease (IBD; n = 4); infec-
tion (n = 3); allergic reaction (n = 2); cardio-vascular dis-
ease (n = 1); demyelization problems (n = 1)), both
inefficacy and adverse events (n = 5; 13%: diarrhea or IBD
(n = 2); infection (n = 1); allergic reaction (n = 1); uveitis
(n = 1)), or other reasons (n = 6; 15%: good initial
response, own choice (n = 3); pregnancy wish (n = 2); lost
to follow-up (n = 1)).
Effect of TNF-a blocking therapy on bone turnover
Data of the 72 AS patients who were still using their first
TNF-a blocking agent after three years were analyzed to
investigate the effect of TNF-a blocking therapy on bone
turnover (Table 2). TNF-a blocking therapy resulted in a
significant increase in the bone formation marker BALP
Z-score after three months (P < 0.001) and BALP Z-score
continued at a higher level up to three years. The bone
formation marker PINP Z-score was found to be signifi-
cantly increased only after three and 24 months of TNF-a
blocking therapy (P < 0.05). The bone resorption marker
sCTX Z-score decreased significantly after three months
(P < 0.001) and remained decreased during three years of
treatment (Figure 1). The course of the absolute BTM
values, analyzed separately for male and female patients
because of gender differences in BTM, were in line with
the results for the BTM Z-scores (data not shown).
Lumbar spine and hip BMD Z-scores improved signifi-
cantly after one year of TNF-a blocking therapy (P <
0.001). Subsequently, the lumbar spine BMD Z-score
increased further after two and three years (P < 0.05 and
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P < 0.01, respectively). The hip BMD Z-score tended to
increase further after two years (P = 0.050), but remained
stable after two to three years of treatment (P = 0.780)
(Figure 2).
Predictive value of early change in bone turnover
Data of 105 AS patients were analyzed to investigate the
predictive value of early change (0-3 months) in BTM
for treatment discontinuation; 72 patients who contin-
ued versus 33 patients who discontinued their first
TNF-a blocking agent because of inefficacy and/or
adverse events. Patients who discontinued treatment due
to other reasons (n = 6) were excluded from this analy-
sis. Baseline to three months decrease in BASDAI,
ASDASCRP, patient’s GDA, physician’s GDA and sCTX
Z-score were inversely associated with time to disconti-
nuation of TNF-a blocking therapy in univariate Cox
regression. Multivariate analysis showed that baseline to
three months decrease in sCTX Z-score (HR: 0.394, 95%
CI: 0.263 to 0.591), ASDASCRP (HR: 0.488, 95% CI:
Table 1 Baseline characteristics of the AS study population
Number of patients 111
Age (yrs) 42.2 ± 10.3
Gender (male) (n, %) 78 (70)
Duration of symptoms (yrs) 16 (1 to 49)
Time since diagnosis (yrs) 9 (0 to 37)
HLA-B27+ (n, %) 88 (81)
History of IBD (n, %) 11 (10)
History of uveitis (n, %) 31 (28)
History of psoriasis (n, %) 9 (8)
Peripheral arthritis (n, %) 21 (19)
Current NSAID use (n, %) 98 (88)
Current DMARD use (n, %) 26 (23)
BASDAI (range 0 to 10) 6.1 ± 1.7 BASDAI ≥ 4 (n, %) 98 (88)
ASDASCRP 3.8 ± 0.8 ASDASCRP ≥ 2.1 (n, %) 105 (96)
Physician’s GDA (range 0 to 10) 5 (1 to 9)
Patient’s GDA (range 0 to 10) 7 (1 to 10)
ESR (mm/h) 22 (2 to 90) Increased ESR (n, %) 86 (78)
CRP (mg/l) 15 (2 to 99) Increased CRP (n, %) 84 (76)
BASFI (range 0 to 10) 6.1 ± 2.0
Chest expansion (cm) 3.0 (0.5 to 10.0)
Modified Schober test (cm) 2.9 (0.1 to 7.0)
Occiput to wall distance (cm) 5.0 (0.0 to 28.0)
Lateral lumbar flexion L (cm) 8.7 ± 4.1
Lateral lumbar flexion R (cm) 8.4 ± 4.3
ASQoL (range 0 to 18) 10 ± 4
BALP (U/L) 17.2 (1.6 to 36.5)
BALP Z-score 0.28 (-2.59 to 5.16)
PINP (μg/l) 45.6 (16.0 to 98.0)
PINP Z-score 0.35 (-1.75 to 3.63)
sCTX (pg/ml) 206.0 (13.4-657.1)
sCTX Z-score -0.34 (-2.58 to 4.01)
LS BMD T-score -0.58 ± 1.41 Osteopenia LS (n, %) 34 (34)
Osteoporosis LS (n, %) 9 (9)
LS BMD Z-score LS Z-score ≤ -2.0 (n, %) 9 (9)
Hip BMD T-score -0.53 ± 1.12 Osteopenia hip (n, %) 38 (37)
Osteoporosis hip (n, %) 2 (2)
Hip BMD Z-score Hip Z-score ≤ -2.0 (n, %) 4 (4)
Values are mean ± SD or median (range) unless otherwise indicated.
AS, Ankylosing Spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BALP, bone-specific-alkaline phosphatase; BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMD, bone mineral density; CRP, C-reactive protein; DMARD, disease-modifying
antirheumatic drug; ESR, erythrocyte sedimentation rate; GDA, global disease activity; HLA-B27+, human leukocyte antigen B27 positive; IBD, inflammatory bowel
disease; L, left; LS, lumbar spine;. NSAID, non-steroidal anti-inflammatory drug; PINP, procollagen type 1 N-terminal peptide; R, right; sCTX, serum C-telopeptide of
type I collagen
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Table 2 Clinical assessments and bone turnover in AS patients still using their first TNF-a blocking agent
Assessment Baseline 3 months P* 6 months P* 12 months P* 24 months P* 36 months P*
BASDAI (range 0 to 10) 6.0 ± 1.7 2.5 ± 1.6 0.000 2.3 ± 1.7 0.000 2.7 ± 2.1 0.000 2.5 ± 1.8 0.000 2.6 ± 1.7 0.000
ASDASCRP 3.9 ± 0.8 1.7 ± 0.7 0.000 1.6 ± 0.7 0.000 1.9 ± 0.9 0.000 1.9 ± 0.8 0.000 1.8 ± 0.8 0.000
Physician’s GDA (range 0 to 10) 5 (1 to 9) 2 (0 to 5) 0.000 1 (0 to 8) 0.000 1 (0 to 7) 0.000 0 (0 to 6) 0.000 0 (0 to 3) 0.000
Patient’s GDA (range 0 to 10) 6 (1 to 10) 2 (0 to 8) 0.000 2 (0 to 8) 0.000 2 (0 to 10) 0.000 2 (0 to 8) 0.000 2 (0 to 7) 0.000
ESR (mm/h) 22 (2 to 90) 5 (2 to 35) 0.000 6 (2 to 36) 0.000 7 (2 to 52) 0.000 9 (2 to 46) 0.000 8 (2 to 48) 0.000
CRP (mg/l) 16 (2 to 99) 3 (2 to 20) 0.000 3 (2 to 21) 0.000 3 (2 to 38) 0.000 3 (2 to 61) 0.000 3 (2 to 57) 0.000
BALP Z-score 0.19 (-1.64 to 3.91) 0.94 (-1.49 to 5.12) 0.000 0.48 (-1.26 to 4.37) 0.000 0.87 (-1.34 to 6.69) 0.000 0.58 (-1.46 to 6.11) 0.000 1.09 (-1.33 to 9.27) 0.000
PINP Z-score 0.36 (-1.75 to 3.63) 0.50 (-1.54 to 4.55) 0.047 0.54 (-1.47 to 5.33) 0.054 0.28 (-1.52 to 5.53) 0.102 0.57 (-1.51 to 7.17) 0.013 0.28 (-1.45 to 2.43) 0.247
sCTX Z-score -0.02 (-2.58 to 4.01) -0.74 (-2.53 to 2.29) 0.000 -0.55 (-2.25 to 3.99) 0.002 -0.45 (-2.23 to 3.11) 0.011 -0.34 (-2.15 to 4.31) 0.119 -0.70 (-2.50 to 4.15) 0.019
LS BMD Z-score -0.36 ± 1.56 0.04 ± 1.42 0.000 0.20 ± 1.39 0.000 0.48 ± 1.61 0.000
Hip BMD Z-score -0.40 ± 1.06 -0.32 ± 0.91 0.000 -0.24 ± 1.01 0.000 -0.16 ± 1.03 0.000
Data of the 72 AS patients who were still using their first TNF-a blocking agent after three years were analyzed.
Values are mean ± SD or median (range).
See Table 1 for abbreviations.
















Figure 1 The effect of three years of TNF-a blocking therapy on BTM in patients with AS. (A) bone formation marker BALP. (B) bone
formation marker PINP. (C) bone resorption marker sCTX. Z-scores were calculated to correct for the normal influence that age and gender have
on bone turnover. Data were available for 100%, 92.6%, 95.4%, 97.2%, 97.2% and 90.3% of the 72 patients at 0, 3, 6, 12, 24 and 36 months,
respectively. Box-and-whisker plots (Tukey): boxes indicate medians with interquartile ranges; + indicate means; whiskers indicate 1.5 times the
interquartile distances; • indicate outliers. a: P < 0.001 compared to values recorded at baseline. b: P < 0.05 compared to values recorded at
baseline. c: P < 0.05 and P < 0.01 compared to values recorded at 6 and 24 months, respectively. d: P < 0.05 and P < 0.01 compared to values
recorded at 12 and 24 months, respectively.
Figure 2 The effect of three years of TNF-a blocking therapy on BMD in patients with AS. (A) lumbar spine BMD. (B) hip BMD. Z-scores
were calculated to correct for age and gender. Data were available for 92.4%, 93.1%, 89.6% and 64.6% of the 72 patients at 0, 12, 24 and 36
months, respectively. Box-and-whisker plots (Tukey): boxes indicate medians with interquartile ranges; + indicate means; whiskers indicate 1.5
times the interquartile distances; • indicate outliers. a: P < 0.001 compared to values recorded at baseline. b: P < 0.05 compared to values
recorded at 12 months. c: P < 0.001 and P < 0.01 compared to values recorded at 12 and 24 months, respectively.
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0.317 to 0.752), and physician’s GDA (HR: 0.739, 95%
CI: 0.600 to 0.909) were independent inversely related
predictors of time to discontinuation of TNF-a blocking
therapy (Table 3).
When the ASDAS was excluded from the analysis,
baseline to three months decrease in sCTX Z-score
(HR: 0.402, 95% CI: 0.273 to 0.593), BASDAI (HR:
0.702, 95% CI: 0.574 to 0.858), and physician’s GDA
(HR: 0.732, 95% CI: 0.602 to 0.891) were selected during
multivariate analysis.
Since the number of female patients was relatively
small, multivariate analysis using absolute BTM values
was performed only in male patients. Baseline to three
months decrease in sCTX (HR: 0.986, 95% CI: 0.979 to
0.993), BASDAI (HR: 0.707, 95% CI: 0.569 to 0.878) or
alternatively, ASDASCRP and physician’s GDA (HR:
0.685, 95% CI: 0.522 to 0.898) were identified as inde-
pendent inversely related predictors of time to treatment
discontinuation.
The accuracy of baseline to three months change in
sCTX Z-score to discriminate between patients who
continued and discontinued TNF-a blocking therapy
during the first three years was moderate, with an AUC
of 0.741 (95% CI: 0.640 to 0.841), and comparable to
the accuracy of early change in ASDASCRP (AUC: 0.790,
95% CI: 0.699 to 0.880) or in physician’s GDA (AUC:
0.730, 95% CI: 0.624 to 0.837).
In addition, baseline to three months change in sCTX
Z-score was significantly associated with disease activity
(BASDAI, ASDASCRP, physician’s and patient’s GDA,
ESR, and CRP), physical function (BASFI), spinal mobi-
lity (chest expansion), and quality of life (ASQoL) at last
follow-up (defined as at three years of TNF-a blocking
therapy or at the moment of treatment discontinuation)
(Table 4).
Discussion
This is the first study that investigates the predictive
value of early changes in bone turnover with regard to
discontinuation of TNF-a blocking therapy in AS. Cur-
rently, in clinical practice, continuation of TNF-a block-
ing therapy is mainly based on subjective measures,
such as the BASDAI and the global opinion of the
patient and the physician. Recent studies showed the
usefulness of the ASDAS as a more objective measure
of disease activity [14-17,21]. However, a purely objec-
tive measure is still lacking in the evaluation process of
TNF-a blocking therapy. The present analysis shows
Table 3 Predictive value of early change in clinical and laboratory parameters for time to treatment discontinuation
Univariate analysis Multivariate analysis
Assessment HR (95% CI) P-value HR (95% CI) P-value
Δ0 to 3 m BASDAI 0.672 (0.579 to 0.780) 0.000 *
Δ0 to 3 m ASDASCRP 0.434 (0.327 to 0.577) 0.000 0.488 (0.317 to 0.752) 0.001
Δ0 to 3 m physician’s GDA 0.643 (0.543 to 0.772) 0.000 0.739 (0.600 to 0.909) 0.004
Δ0 to 3 m patient’s GDA 0.735 (0.641 to 0.844) 0.000 *
Δ0 to 3 m CRP 0.977 (0.954 to 1.002) 0.068 *
Δ0 to 3 m ESR 0.975 (0.950 to 1.001) 0.064 *
Δ0 to 3 m BALP Z-score 1.291 (0.969 to 1.720) 0.081 *
Δ0 to 3 m PINP Z-score 1.014 (0.688 to 1.493) 0.944 **
Δ0 to 3 m sCTX Z-score 0.513 (0.367 to 0.717) 0.000 0.394 (0.263 to 0.591) 0.000
Data of 105 AS patients were analyzed: 72 patients who continued versus 33 patients who discontinued their first TNF-a blocking agent because of inefficacy
and/or adverse events.
Δ0 to 3 m, change from baseline to three months. See Table 1 for other abbreviations.
HR refers to the risk of anti-TNF-a treatment discontinuation per 1 grade or 1 point.
* The variable was not selected during multivariate Cox regression analysis (P ≥ 0.05).
** The variable was not tested in multivariate Cox regression analysis because of a P-value > 0.3 in univariate analysis.
Table 4 Correlations between early change in bone
resorption marker sCTX and clinical assessments at last
follow-up
Δ0 to 3 sCTX Z-score
Assessment at last follow-upa correlation P-value
BASDAI (range 0 to 10) -0.388 0.000
ASDASCRP -0.463 0.000
Physician’s GDA (range 0 to 10) -0.321 0.001
Patient’s GDA (range 0 to 10) -0.260 0.010
ESR (mm/h) -0.273 0.006
CRP (mg/l) -0.288 0.004
BASFI (range 0 to 10) -0.268 0.008
Chest expansion (cm) 0.260 0.010
Modified Schober test (cm) -0.031 0.762
Occiput to wall distance (cm) 0.095 0.350
Lateral lumbar flexion L (cm) 0.096 0.346
Lateral lumbar flexion R (cm) 0.169 0.097
ASQoL (range 0 to 18) -0.296 0.003
Data of 105 AS patients were analyzed.
See Tables 1 and 3 for abbreviations.
a Defined as at three years of TNF-a blocking therapy or at the moment of
treatment discontinuation
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that a baseline to three months’ decrease in sCTX Z-
score was inversely related to time to discontinuation of
TNF-a blocking therapy. Interestingly, sCTX Z-score
remained a significant predictor of treatment disconti-
nuation in the presence of ASDAS and physician’s GDA,
which underlines the value of sCTX in addition to the
currently used measures. The accuracy of decrease in
sCTX Z-score from baseline to three months in predict-
ing treatment continuation was comparable to the mod-
erate accuracy of early decrease in ASDAS or physician’s
GDA. Furthermore, early decrease in sCTX Z-score was
significantly associated with good long-term response
regarding disease activity, physical function, spinal mobi-
lity, and quality of life. Based on these results, early
change in sCTX can be useful as an objective biomarker
in the evaluation of TNF-a blocking therapy in patients
with AS. A major advantage of BTM is that they can
easily be measured in the blood of patients at different
time points with relatively low costs. sCTX is widely
available on automated immunoassay analysers or as
ELISA. However, it is important to standardize the serum
sample collection to reduce variability within and
between patients [18].
Until now, several studies investigated the influence of
TNF-a blocking therapy on bone formation and bone
resorption up to one year of treatment [19-23]. The pre-
sent study shows that three years of TNF-a blocking ther-
apy resulted in a significant increase in the bone formation
marker BALP, which plays a central role in the mineraliza-
tion process of bone, at all time-points compared to base-
line, while the effect on the bone formation marker PINP,
a product of collagen formation, was found to be less evi-
dent. Furthermore, a significant decrease in the bone
resorption marker sCTX, a product of collagen degrada-
tion, was found during three years of TNF-a blocking
therapy. The significant increase in bone formation is in
line with previous findings after one year of TNF-a block-
ing therapy [19-21]. Until now, no clear effect of TNF-a
blocking therapy on bone resorption was reported
[19,21-23]. In the present study, we had the unique avail-
ability of a healthy reference cohort on BTM, which allows
us to correct the BTM levels of an individual AS patient
for age and gender (using Z-scores). In this way, the rate
of bone turnover can be studied without the confounding
influence of age and gender, similar to the methodology of
interpreting BMD. Nevertheless, our findings using the
absolute BTM values (analysis split for gender) were in
line with the results for the BTM Z-scores (data not
shown).
The changes in BTM over time found in this study can-
not be specifically attributed to TNF-a blocking therapy
because a placebo group is lacking. Visvanathan et al.
showed no significant changes in BALP or sCTX during
24 weeks of placebo treatment [23], which indicates that
the present significant changes in BTM compared to
baseline are the result of TNF-a blocking therapy. How
these results fit into the pathogenesis of AS remains to
be studied.
Importantly, the present results regarding BTM should
not be extrapolated to any possible effect of TNF-a block-
ing therapy on radiographic progression in AS since no
imaging method was used to measure new bone formation
resulting in the formation of syndesmophytes and joint
ankylosis. Furthermore, long-term observation is needed
in order to see any effect of TNF-a blocking therapy on
new bone formation in patients with AS.
Interestingly, both lumbar spine and hip BMD improved
significantly during three years of TNF-a blocking therapy,
which can be explained by the increase in mineralization
and decrease in bone resorption. Alternatively, the
increase in lumbar spine BMD may in part be confounded
by the progression of formation of ligament calcifications
and fusion of facet joints [5,29,30]. However, we expect
that excessive bone formation will only have minor influ-
ence on the increase in lumbar spine BMD found in the
present study, since previous studies reported a radiologi-
cal progression of approximately one point in Modified
Stoke Ankylosing Spondylitis Spinal Score (mSASSS; on a
scale of 0 to 72) after two years of TNF-a blocking therapy
[31-33]. Moreover, the improvement in lumbar spine and
hip BMD after TNF-a blocking therapy is in line with pre-
vious findings [23,34].
Conclusions
This prospective longitudinal observational cohort study
shows that three years of TNF-a blocking therapy results
in a bone turnover balance that favors bone formation
(especially mineralization), in combination with continu-
ous improvement of lumbar spine BMD. Furthermore, a
baseline to three months’ decrease in sCTX Z-score is
identified as a significant inversely related predictor of
time to treatment discontinuation, independent from
ASDAS and physician’s GDA. Based on these results, early
change in the bone resorption marker sCTX seems useful
as a purely objective biomarker in the evaluation of TNF-
a blocking therapy in AS, in addition to the currently used
more subjective measures.
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